A-Z> Targets for Antibody-Drug Conjugates
ADCs (Antibody-drug conjugates) are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens with highly potent anti-cancer agents linked via a chemical linker, while sparing normal cells from damage, potentially minimizing the side effects associated with cancer therapy. Currently, there are nine approved drugs on the market.
List of ADCs have been approved
The idea for the ADCs was first proposed by Paul Ehrlich, Nobel Laureate from Germany, in the early 20th century. Mylotarg™, the first ADCs, was FDA-approved in 2000 and five ADC drugs have been approved in 2019. The global ADCs development market is expected to reach $12.9 billion, according to Evaluate Pharma and BCG. We believe that with the development hotspot of ADCs from hematomas to solid tumors, choosing the suitable drug target proteins will become more and more important.
ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI protocols are available for free. In addition, over expressed cell lines and kit products will be coming soon.
ACROBiosystems is continuously developing more high-quality targeting proteins of ADCs. If you have any suggestions or customized requirements, please contact us.
Fig1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Fig 2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.
Fig 3.Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.
Fig 4.Loaded Herceptin (Trastuzumab) on AHC Biosensor, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 0.825 nM as determined in BLI assay.
Fig 5.Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.
Fig 6.Loaded Erbitux (Cetuximab) on AHC Biosensor, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.23 nM as determined in BLI assay.
This web search service is supported by Google Inc.
